<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537884</url>
  </required_header>
  <id_info>
    <org_study_id>UBX1325-01</org_study_id>
    <nct_id>NCT04537884</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration</brief_title>
  <official_title>A Phase 1, Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unity Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal&#xD;
      injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular&#xD;
      Age-Related Macular Degeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, first-in-human (FIH), single-ascending dose (SAD) study&#xD;
      consisting of approximately 4 cohorts. The total number of patients will be at least 3 per&#xD;
      cohort plus 3 additional patients in the maximum tolerated dose (MTD) cohort in order to&#xD;
      address the primary objective. Up to an additional 6 nAMD patients will be enrolled in the&#xD;
      highest dose cohort. A single dose of UBX1325 will be administered intravitreally and all&#xD;
      patients will be followed for approximately 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular and systemic safety and tolerability of a single intravitreal injection of UBX1325 evaluated by the incidence of dose limiting toxicities (DLTs) and treatment emergent adverse events (TEAEs)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of UBX1325 following a single intravitreal injection</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Treatment with UBX1325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UBX1325, single intravitreal injection, ascending dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UBX1325</intervention_name>
    <description>Investigational drug intravitreal injection</description>
    <arm_group_label>Treatment with UBX1325</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  nAMD patients who, in the opinion of the Investigator, are inadequately responding to&#xD;
             or failed current treatment options.&#xD;
&#xD;
          -  Active choroidal neovascularization (CNV) associated with age-related macular&#xD;
             degeneration as evidenced on FA and SD-OCT at Day 1, including presence of&#xD;
             intraretinal or subretinal fluid.&#xD;
&#xD;
          -  BCVA in the study eye (most affected) of 70 Early Treatment Diabetic Retinopathy Study&#xD;
             (ETDRS) letters or worse at screening and on Day 1.&#xD;
&#xD;
          -  Patients who have the capacity to give informed consent and who are willing and able&#xD;
             to comply with all study-related procedures and assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any ocular/intraocular/periocular infection or inflammation in either eye in the past&#xD;
             4 weeks prior to screening.&#xD;
&#xD;
          -  Subretinal hemorrhage with bleeding area ≥4 disc area in the study eye&#xD;
&#xD;
          -  Concomitant therapy with anti-VEGF therapies (e.g., Avastin®, Lucentis®, or Eylea®) or&#xD;
             previous use of these agents in the study eye within approximately 28 days of study&#xD;
             enrollment&#xD;
&#xD;
          -  Any retinovascular disease or retinal degeneration other than nAMD in the study eye.&#xD;
&#xD;
          -  History of systemic and intraocular steroid use for 6 months prior to Day 1. The use&#xD;
             of intravitreal nonbiodegradable steroid implants (ex. Iluvien®, Yutiq®, Retisert®) is&#xD;
             prohibited.&#xD;
&#xD;
          -  Significant media opacities, including cataract, which might interfere with VA,&#xD;
             assessment of toxicity, or fundus imaging.&#xD;
&#xD;
          -  Any uncontrolled medical condition that, in the opinion of the investigator, would&#xD;
             preclude participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Dananberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNITY Biotechnology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salehi Retina Institute</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidWest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal disease</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

